Filtered By:
Specialty: Drugs & Pharmacology
Drug: Warfarin

This page shows you your search results in order of date. This is page number 17.

Order by Relevance | Date

Total 300 results found since Jan 2013.

Factors influencing quality of anticoagulation control and warfarin dosage in patients after aortic valve replacement within the 3 months of follow up.
Abstract Warfarin dosage estimation using the pharmacogenetic algorithms has been shown to improve the quality of anticoagulation control in patients with atrial fibrillation. We sought to assess the genetic, demographic and clinical factors that determine the quality of anticoagulation in patients following aortic valve replacement (AVR). We studied 200 consecutive patients (130 men) aged 63 ± 12.3 years, undergoing AVR, in whom warfarin dose was established using a pharmacogenetic algorithm. The quality of anticoagulation within the first 3 months since surgery was expressed as the time of international normali...
Source: J Physiol Pharmacol - May 31, 2016 Category: Drugs & Pharmacology Authors: Wypasek E, Mazur P, Bochenek M, Awsiuk M, Grudzien G, Plincer D, Undas A Tags: J Physiol Pharmacol Source Type: research

Establishing Edoxabans Role in Anticoagulation
Conclusion Based on the 3 clinical trials, edoxaban appears to be a safe and effective factor Xa inhibitor in patients with a creatinine clearance of <95 mL/min. It will serve as an alternative anticoagulant for those with a preference for once-daily dosing and/or taking medications that interact with the CYP450 system.
Source: Journal of Pharmacy Practice - May 10, 2016 Category: Drugs & Pharmacology Authors: Guirguis, E., Brown, D., Grace, Y., Patel, D., Henningfield, S. Tags: Review Articles Source Type: research

Direct oral anticoagulants for stroke prevention in patients with atrial fibrillation: meta‐analysis by geographic region with a focus on european patients
ConclusionThe DOAC did not provide additional benefit in reducing the risk of stroke/SEE compared with warfarin in European patients with AF, but were generally associated with a lower bleeding tendency than warfarin regardless of geographic region. This article is protected by copyright. All rights reserved.
Source: British Journal of Clinical Pharmacology - May 9, 2016 Category: Drugs & Pharmacology Authors: Antonio A. Gómez‐Outes, Ana‐Isabel Terleira‐Fernández, Gonzalo Calvo‐Rojas, Mª. Luisa Suárez‐Gea, Emilio Vargas‐Castrillón Tags: Systematic Review Source Type: research

Stroke in a Young Woman as a Presenting Manifestation of Membranous Nephropathy
Stroke is one of the most severe complications of nephrotic syndrome (NS), only a few cases have been reported in previous literature. Some of those cases are not clear about whether the stroke was purely caused by NS because they also had other risk factors for stroke, such as old age, hypertension. A recent study showed that serum albumin less than 2.8 g/dL is a risk factor for thromboembolic events (venous thromboembolic events). Anticoagulation is suggested for patients with NS with low albumin by KIDIGO guideline 2012. Here, we describe a case in which a young patient presented with stroke as an initial symptom of mem...
Source: American Journal of Therapeutics - May 1, 2016 Category: Drugs & Pharmacology Tags: Case Reports Source Type: research

Is Dabigatran As Effective As Warfarin on Cardiac Thrombus in a Patient With Atrial Fibrillation? A Challenging Question
Atrial fibrillation (AF) is an important risk factor for cardioembolic stroke. Warfarin is an effective treatment in reducing the risk of cardioembolic stroke in patients with AF. New anticoagulants have been widely using for stroke prophylaxis in patients with nonvalvular AF. Previous studies have suggested that thrombolytic therapy is effective treatment choice in patients with pulmonary embolisms. Warfarin therapy is also effective on prevention or treatment of cardiac thrombus in patients with AF. However, there are no evidence-based data on treatment of cardiac thrombus with new oral anticoagulants in patients with AF...
Source: American Journal of Therapeutics - May 1, 2016 Category: Drugs & Pharmacology Tags: Case Reports Source Type: research

Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care
ConclusionsRivaroxaban was associated with similar or lower stroke rates, but higher bleeding and mortality rates. Channeling of rivaroxaban towards elderly and less healthy patients may have generated residual confounding. In particular, our findings cannot stand alone when deciding which oral anticoagulant to prescribe. Copyright © 2016 John Wiley & Sons, Ltd.
Source: Pharmacoepidemiology and Drug Safety - April 30, 2016 Category: Drugs & Pharmacology Authors: Anders Gorst‐Rasmussen, Gregory Y. H. Lip, Torben Bjerregaard Larsen Tags: Original Report Source Type: research

Well-managed warfarin still useful for stroke prevention
A study of 40,000 patients with atrial fibrillation suggests that warfarin is a valid treatment for stroke prevention.
Source: Clinical Pharmacist - April 27, 2016 Category: Drugs & Pharmacology Source Type: research

Cost‐Effectiveness of High‐Dose Edoxaban Compared with Adjusted‐Dose Warfarin for Stroke Prevention in Non–Valvular Atrial Fibrillation Patients
ConclusionsHigh‐dose edoxaban appears to be an economically dominant strategy when compared with adjusted‐dose warfarin for the prevention of stroke in NVAF patients with a Clcr of 15–95 ml/minute and an appreciable risk of stroke.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - April 26, 2016 Category: Drugs & Pharmacology Authors: Elaine Nguyen, Florence Egri, Elizabeth S. Mearns, Charles M. White, Craig I. Coleman Tags: Original Research Article Source Type: research

Pharmacological Prophylaxis for Venous Thromboembolism Among Hospitalized Patients With Acute Medical Illness: An Electronic Medical Records Study
The objectives of this study were to examine pharmacological prophylaxis against VTE among hospitalized medically ill patients and to assess demographic and clinical correlates related to VTE prophylaxis. A retrospective (1999–2010) electronic medical records study included patients aged 40 years and older hospitalized for at least 3 days, with significant medical illness or with a VTE hospitalization 30–365 days before admission. Each patient's first qualifying hospitalization was analyzed. Exclusions were if VTE treatment was started within 1 day of admission, or if warfarin (and not heparin or enoxaparin) was used. ...
Source: American Journal of Therapeutics - March 1, 2016 Category: Drugs & Pharmacology Tags: Original Articles Source Type: research

Cost‐Effectiveness of High‐Dose Edoxaban Compared to Adjusted‐Dose Warfarin for Stroke Prevention in Non‐Valvular Atrial Fibrillation Patients
ConclusionsHigh‐dose edoxaban appears to be an economically dominant strategy when compared to adjusted‐dose warfarin for the prevention of stroke in NVAF patients with a CrCl of 15‐95 mL/minute and an appreciable risk of stroke.This article is protected by copyright. All rights reserved.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - February 29, 2016 Category: Drugs & Pharmacology Authors: Elaine Nguyen, Florence Egri, Elizabeth S. Mearns, Charles M. White, Craig I. Coleman Tags: Original Research Article Source Type: research

Dabigatran Versus Warfarin After Bioprosthesis Valve Replacement for the Management of Atrial Fibrillation Postoperatively: DAWA Pilot Study
Conclusions The use of dabigatran appears to be similar to warfarin in preventing the formation of intracardiac thrombus. Trial Registration Clinicaltrials.gov NCT01868243.
Source: Drugs in R&D - February 18, 2016 Category: Drugs & Pharmacology Source Type: research

Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Authors: Dzeshka MS, Lip GY Abstract INTRODUCTION: Oral anticoagulation is central to the management of patients with atrial fibrillation (AF) and at least one additional stroke risk factor. For decades, the vitamin K antagonists (e.g. warfarin) remained the only oral anticoagulant available for stroke prevention in AF. The non-vitamin K oral anticoagulants (NOACs) are now available, and these drugs include the direct thrombin inhibitors and factor Xa inhibitors. The latter class includes edoxaban, which has recently been approved for stroke prevention in AF by the United States Food and Drug Administration and the...
Source: Expert Opinion on Pharmacotherapy - February 14, 2016 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin
We describe the first case report, to our knowledge, documenting a drug interaction between phenytoin and dabigatran by using laboratory measurements of dabigatran serum concentrations. A 45‐year‐old African‐American man was admitted to the inpatient cardiology service following defibrillations from his implantable cardioverter defibrillator. The patient was evaluated and received appropriate antitachycardia pacing for atrial tachyarrhythmias for an episode of ventricular tachycardia (VT), and antiarrhythmic therapy with sotalol was initiated to reduce both his AF and VT burden. On review of the patient's medications...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - February 5, 2016 Category: Drugs & Pharmacology Authors: Barbara S. Wiggins, Amanda Northup, Dominic Johnson, Jeffrey Senfield Tags: Case Report Source Type: research

The Use of Novel Oral Anticoagulants in Atrial Fibrillation.
Authors: Ansari U, Behnes M, Fastner C, Akin I Abstract Atrial fibrillation is known to be associated with an increased risk of ischaemic stroke and systemic embolism. After stratification using various risk calculation scores, patients were traditionally prescribed anticoagulants in the form of Aspirin or the traditional Vitamin K Antagonists. The use of Warfarin has proven to reduce incidents of ischaemic stroke; however its use has several limitations. The necessity for strict anticoagulation monitoring so as to maintain the narrow therapeutic range as measured by the international normalized ratio (INR) between...
Source: Cardiovascular and Hematological Disorders Drug Targets - December 19, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation
Conclusions After 2 years, the persistence with any anticoagulant treatment was high in patients with non-valvular AF. Our results indicate better persistence with warfarin and apixaban than with dabigatran or rivaroxaban in regular care.
Source: European Journal of Clinical Pharmacology - November 27, 2015 Category: Drugs & Pharmacology Source Type: research